Stockscreener 앱 받기
3.74
3.31%
0.12
시간 외 거래:
3.74
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARMP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program - Benzinga
Form 8K Armata Pharmaceuticals Inc For: 23 September By Investing.com - Investing.com Australia
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target - TradingView
Armata Pharmaceuticals Gets $3.7 Million in Non-Dilutive US Funding - Minichart
Form 8K Armata Pharmaceuticals Inc For: 23 September - Investing.com India
Armata secures new U.S. funding for AP-SA02 Phase 3 - TipRanks
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development - prnewswire.com
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials - GuruFocus
H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data - Investing.com
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Australia
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates - prnewswire.com
Armata Pharmaceuticals Inc. (ARMP) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation - Yahoo Finance
ARMP Stock Draws Attention As New Phage Data Backs Late-Stage Program - timothysykes.com
Armata Pharmaceuticals stock rises on FDA breakthrough designation By Investing.com - Investing.com Canada
ARMP Stock Pops As Peer-Reviewed Phage Data Backs Late-Stage Program - StocksToTrade
ARMP Stock Draws Bullish Focus After New Phage Breakthrough - timothysykes.com
Form 8K Armata Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Canada
Armata wins FDA Breakthrough Therapy for AP-SA02 - TipRanks
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 - PR Newswire
Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote, News & History - Benzinga
Deborah Birx is scheduled to present for Armata on Sept. 16 - Stock Titan
Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP? - StockInvest.us
Armata Pharmaceuticals (ARMP) Advances Phage Therapy Research Am - GuruFocus
Armata Pharmaceuticals publishes phage research findings By Investing.com - Investing.com Australia
Armata Pharmaceuticals publishes phage research findings - Investing.com
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials - PR Newswire
Armata Pharmaceuticals Inc. (ARMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Armata Pharmaceuticals Inc. (ARMP) Peer Comparison – Compare with Others - Value Research
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Armata (ARMP) Results Check: EPS Falls Short of Its Estimate in the Latest Session; Price Reaction - careplusvn.com
Armata (ARMP) Today: Finishes 12.82% Lower at $4.42; Chart View: Price Remains Between $4.20 Support and $4.64 Resistance in the Available RecordLow Volatility Picks - vinanet.vn
Armata (ARMP) Earnings Report: EPS Falls Short of Its Estimate on the Day; Investor Response: The Market Price Advances 11.18%Earnings Preview - vinanet.vn
Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP - MarketBeat
Armata (ARMP) Earnings Review: The EPS Result Is Below Expectation under the Current Snapshot; Post-Report Move: Shares Rise 1.79%Geographic Revenue Trends - careplusvn.com
ARMP Q1 2026 Earnings: Severe EPS Miss Deepens as Clinical-Stage Costs Pressure Results - vinanet.vn
HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings - MarketBeat
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharma earnings beat by $0.17, revenue topped estimates - Investing.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
10-Q: Armata Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
ARMP Q1 2026 Earnings: Deep EPS Miss and No Revenue Spotlight Clinical-Stage Cash BurnEarnings Call Highlights - careplusvn.com
[ARMP] Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-than-Expected Net LossQuarterly Financial Update - vinanet.vn
Armata Pharmaceuticals (ARMP) Dips 2% as Shares Approach Key Support at $4.37Breakout Confirmation - vinanet.vn
Armata Pharmaceuticals (ARMP) Slips 5% as Biotech Volatility Weighs on Clinical-Stage StockAnalyst Downgrade Signals - careplusvn.com
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Net Loss Wide of Estimates, Cash Burn Remains a FocusMargin Compression Risk - careplusvn.com
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Wider-than-Expected Loss Intensifies Investor CautionPre-Announcement Alert - careplusvn.com
ARMP|Armata Pharmaceuticals Inc|Price:5.150|Chg%:+0.490 - TradingKey
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Cash Flow - TradingKey
TradingKey - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
3.06%
2.55%
자본화:
|
볼륨(24시간):